Massive Bio operates an AI-powered trial matching platform that automatically matches patient data to cancer trial criteria to speed access to treatment options. The company reports onboarding more than 100,000 patients onto its platform. Its technology is positioned to enable broader, more inclusive, population-based recruitment for life sciences companies beyond traditional site-specific methods. Massive Bio is pursuing multi-country expansion to capture the global oncology clinical trial enrollment market. The company has been accelerating product and growth efforts through senior hires to its C-suite and executive team. Financially, Massive Bio closed a $16.5 million funding round in 2022, bringing total capital raised to $23.3 million since inception. Massive Bio provides an AI-powered, data-rich platform and concierge services to identify, pre-screen and enroll cancer patients into clinical trials. The company has launched initiatives such as an Oncology Clinical Trial Command Center (OCTCC) and a 100K Cancer Clinical Trial Singularity Program, and offers web and mobile (iOS/Android) tools. Massive Bio reports reaching 60,000 cancer patients and serving 26 enterprise customers, 88% of which are large pharmaceutical companies and CROs. Over the past 12 months the company expanded into 12 countries and grew to a global workforce of 70 employees. The leadership says the business is cost-efficient and generating consistent revenue and client growth despite the economic downturn. Massive Bio aims to scale its operations globally, expand its product offering in oncology clinical trial enrollment, and invest further in marketing and technology. Massive Bio operates an AI-driven platform that connects cancer patients and community oncologists to biopharmaceutical clinical trials, aiming to improve access and match rates. The company controls the patient enrollment value chain, including patient identification, AI-based virtual pre-screening outside the site, and resolving last-mile enrollment issues. It provides patient recruitment, site selection, and real-world data services and serves close to two dozen pharmaceutical companies and CROs. Founded in 2015 and headquartered in New York City, Massive Bio has historically relied mostly on revenue generated by customer demand to fuel growth. In 2020 the company experienced rapid, exponential demand accelerated by COVID-19 and a rapidly growing roster of clients globally. The recent financing is intended to enable the company to scale to meet demand in the U.S. and overseas and to expand globally.

Total raised

$28M

Funding rounds

3

Latest round

Equity

Latest activity

Dec 2022